Intrexon (XON) Posts Q4 GAAP EPS of 19c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Synthetic Biologics (SYN) SYN-005 Preclinical Results to Be Highlighted at ECCMID
March 2, 2015 8:41 AM ESTSynthetic Biologics, Inc. (NYSE: SYN) announced that preclinical results supporting the development of SYN-005 for the treatment of Pertussis will be highlighted at ECCMID 2015 (European Congress of Clinical Microbiology and Infectious Diseases), April 25-28, in Copenhagen, Denmark. Two posters will be presented under the Respiratory Infections category all four days at ECCMID on 50 ePoster stations, as follows:
Title: Antibody Cocktail Effectively Treats Pertussis in a Baboon Disease ModelAuthors: J. A. Maynard1, A. Nguyen1, E. Wagner1, J. Laber1, L. Goodfield2, W. Smallridge2, E. T.... More
